CHARM Therapeutics
4 known investors
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.
AI & Machine LearningBiotechHealthtech
Investors · 4
Frequently asked questions
- What does CHARM Therapeutics do?
- CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.
- Who are CHARM Therapeutics's investors?
- CHARM Therapeutics's investors include F-Prime Capital Partners, OrbiMed, Axial VC, NVentures.